Recommended Composition of Influenza Virus Vaccines
for use in the 2014 Southern Hemisphere Influenza Season.
Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N 1 influenza virus vaccines
Influenza virus vaccines
in children and their impact on the incidence of otitis media.
This indication is based on the immune response elicited by the seasonal trivalent Influenza Virus Vaccines
manufactured by CSL (Afluria([R])).
Fluzone, Fluzone Quadrivalent, Fluzone Intradermal, and Fluzone High-Dose vaccines are inactivated influenza virus vaccines
indicated for active immunization for the prevention of influenza disease caused by influenza subtype A and type B viruses contained in the vaccines.
Current influenza virus vaccines
attempt to induce strong antibody responses against the viral glycoproteins hemagglutinin (HA) and, with lesser emphasis, neuraminidase (NA) because their protective efficacy is well documented.
Medicare Part B began paying for influenza virus vaccines
in 1998 and PPV in 1981.
Inactivated influenza virus vaccines
have been available in the United States for more than 50 years.
This age group typically does not respond as well to the standard dose of influenza virus vaccines
as younger individuals because they have weakened immune systems.
Clinical reactions and serologic responses in healthy children aged six to 35 months after two-dose regimens of inactivated A/New Jersey/76 influenza virus vaccines
Steve Bell, vice president of research and pre-clinical development, presented a case study highlighting the potential of BioVant(TM), the Company's calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, in influenza virus vaccines
, including H5N1 avian influenza, or bird flu.
market with a combined total of 30-35 million doses of the seasonal influenza virus vaccines
Fluarix(R) (Influenza Virus Vaccine
) and FluLaval(TM) (Influenza Virus Vaccine
) - up from approximately 25 million doses in the 2006-2007 flu season.